IN.PACT AV

Drug-Coated Balloon (DCB)
for Arteriovenous (AV) Access Maintenance

The IN.PACT™ AV drug-coated balloon (DCB) enables you to get ahead of AV fistula restenosis by treating the cause — not just the symptoms — of fistula stenosis helping to preserve the fistula for dialysis.1

VIEW BROCHURE

Overview

NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES LARGEST AV DCB  PIVOTAL TRIAL*

READ MANUSCRIPT

GET AHEAD OF AV FISTULA RESTENOSIS1

In the largest randomized AV DCB study conducted,* IN.PACT AV DCB reduced interventions by more than 56% over PTA.1 It is the only AV DCB on the market to meet its primary effectiveness endpoint.

SEE THE DATA

INDICATIONS

The IN.PACT AV paclitaxel-coated PTA balloon catheter is indicated for percutaneous transluminal angioplasty, after appropriate vessel preparation, for the treatment of obstructive lesions up to 100 mm in length in the native arteriovenous dialysis fistulae with reference vessel diameters of 4 to 12 mm.

PRODUCT DETAILS

The IN.PACT AV DCB is a clinically demonstrated endovascular therapy for end-stage renal disease (ESRD) patients with a narrowed AV fistula. It delivers an antiproliferative drug (paclitaxel) to the vessel to inhibit neointimal hyperplasia (NIH), the primary cause of AV fistula stenosis. The proprietary design enables the IN.PACT AV DCB to deliver sustained drug levels and unparalleled clinical results.1

EFFICIENT DELIVERY

A proprietary combination of paclitaxel drug and urea excipient allows rapid transfer of the antiproliferative drug to the vessel wall.2

sustained duration

Reservoirs of the drug stay in the vessel wall, capable of delivering effective paclitaxel levels by residing in the vessel for up to 180 days.2

Extended Effect

Uniquely combining an appropriate dosage for an appropriate amount of time,2 the IN.PACT AV DCB can reduce the need for reinterventions and catheter-based dialysis and the related risks of infection and all-cause mortality.1

HOW IT WORKS

MECHANISM OF ACTION

The IN.PACT AV DCB is coated with a unique combination of paclitaxel, an antiproliferative drug, and an excipient, urea. The unique drug dose and excipient formulation showed unmatched results versus PTA in the largest AV DCB clinical trial.1

SPECIFICATIONS

Product Characteristic Description

Balloon Coating

Paclitaxel and urea

Paclitaxel Drug Dose

3.5 μg/mm2

Balloon Diameters

4.0 to 12.0 mm

Balloon Fold Configuration

4.0 mm 3 folds; 5 — 12 mm 6 folds

Balloon Lengths

40 to 120 mm

Catheter Effective Length

40, 80, and 130 cm

Guidewire Compatibility

0.035"

Catheter Shaft Design

Over-the-wire (OTW)

Shaft Diameter

5 Fr

Introducer Sheath Compatibility

4.0 mm — 5 Fr; 5.0–6.0 mm — 6 Fr; 7.0–10 mm — 7 Fr; 12.0 mm — 9 Fr.

Nominal Balloon Pressure

4.0–9.0 mm — 8 atm; 10.0–12.0 mm — 6 atm

Rated Burst Pressure

4.0–7.0 mm — 14 atm; 8.0–9.0 mm — 10 atm; 10.0 mm — 9 atm; 12.0 mm — 9 atm

Sterilization Method

Ethylene oxide (ETO)

Ordering Information

Document thumbnail
pdf Clinical Trial Overview (.pdf)

IN.PACT AV Access Clinical Trial results

519KB

View Trial Results
pdf Trial Comparison Sheet (.pdf)

Results from separate trials comparing DCBs to standard PTA alone for AV fistula maintenance

562KB

View Comparison
pdf Patient Information Booklet (.pdf)

Patient guide for AV fistula maintenance

7.0MB

Download Patient Guide

IN.PACT AV TRIAL RESULTS PUBLISHED

in the New England Journal of Medicine.

REVIEW MANUSCRIPT

PRODUCT

MANUALS

Access product manuals from the Medtronic Manual Library by searching for the product name or product number.

Visit Library

Contact Information

CardioVascular Lifeline Customer Support

+1-763-526-7890
rs.cstechsupport@medtronic.com

Orders

+1-763-514-8510
rs.cuvasorders@medtronic.com

24-hour Technical Support

+1-763-514-4000 (Worldwide)
*

The largest global, randomized, AV fistula drug-coated balloon study conducted, with subjects from Japan, New Zealand, and the United States.

Results are from different studies and may vary in a head-to-head comparison.

References

1

Lookstein RA, et al. Drug-Coated Balloons for Dysfunctional Dialysis Arteriovenous Fistulas. N Engl J Med 2020;383:733-42. DOI: 10.1056/NEJMoa1914617. Highlighted results reported at both 180 and 210 days.

2

Data on file at Medtronic.

Reduction in reinterventions: Defined as the number of interventions required to maintain target lesion primary patency calculated at 210 days.